Read More

Mydecine Announces 1-for-50 Reverse Stock Split

The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding shares on a base of 1-for-50. According to Mydecine, the consolidation is expected to reduce the number of common shares from 268,515,954 to  5,370,319.


Read More

Understanding The Psilocybin Supply Chain: Every Production Method Explained

Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.